Tag Archives: innovation

‘The Debate of the Next Decade’ AI Debate 2 Explores AGI and AI Ethics – Synced

For the second year in a row, Gary Marcus, CEO and founder of Robust.AI and New York University Professor Emeritus, went live on the AI Debate series hosted by Montral.AI. This time it was not to spar with Turing Award winner Yoshua Bengio, but to moderate three panel discussions on how to move AI forward.

Last year, in the first annual December AI Debate, Yoshua Bengio and I discussed what I think is one of the key debates in the last decade are big data and deep learning alone enough to get to artificial general intelligence (AGI)? said Marcus as he launched what he termed the debate of next decade how can we take AI to the next level?

This years AI Debate 2 Moving AI Forward: An Interdisciplinary Approach was held again on the day before Christmas Eve and featured 16 panellists from leading AI researchers and practitioners to psychology professors, neuroscientists, and researchers on ethical AI. The four-hour event included three panel discussions: Architecture and Challenges, Insights from Neuroscience and Psychology, and Towards AI We Can Trust.

Fei-Fei Li kicked off the Architecture and Challenges panel with the presentation In search of the next AI North Star. Li is a researcher in Computer Vision and AI + Healthcare, a computer science professor at the Stanford University, co-director Stanford Human-Centered AI Institute, and cofounder and chair at AI4ALL.

Problem formulation is the first step to any solution, and AI research is no exception, Li explains. Object recognition as one critical functionality of human intelligence has guided AI researchers to work on deploying it in artificial systems for the past two decades or so. Inspired by the research on the evolution of human/animal nervous systems, Li says she believes the next critical AI problem is how to build interactive learning agents that use perception and actuation to learn and understand the world.

Machine Learning Researcher Luis Lamb, whos also a professor of the Federal University of Rio Grande do Sul in Brazil, and Secretary of State for Innovation, Science and Technology, State of Rio Grande do Sul, Brazil, thinks the current key problem in AI is how to identify its necessary and sufficient building blocks, and how to develop trustworthy ML systems that are not only explainable, but also interpretable.

Richard Sutton, distinguished research scientist at DeepMind and a computing science professor at the University of Alberta in Canada, agrees that its important to understand the problem before offering solutions. He points out that AI has surprisingly little computational theory its true in neuroscience that were missing a sort of higher-level understanding of the goals and purposes of the overall mind, and thats also true in AI, he says.

AI needs an agreed-upon computational theory, Sutton explains, and he regards reinforcement learning (RL) as the first computational theory of intelligence, which is explicit about its goal the whats and the whys of intelligence.

It is well-established that AI can solve problems, but what we humans can do is still very unique, says Ken Stanley, an OpenAI research manager and a courtesy computer sciences professor at the University of Central Florida. As humans exhibit open-ended innovation, AI researchers similarly need to pursue open-endedness in artificial systems.

Stanley emphasizes the importance of understanding what makes intelligence a fundamental aspect of humanity. He identifies several dimensions of intelligence that he believes are neglected: divergence, diversity preservation, stepping stone collection, etc.

Judea Pearl, Turing Award winner for fundamental contributions to AI through the development of a calculus for probabilistic and causal reasoning and director at the UCLA Cognitive Systems Laboratory, argues that next-level AI systems need added knowledge instead of remaining data-driven. This idea that knowledge of the world or common sense is one of the fundamental missing pieces is shared by Yejin Choi, an associate professor at the University of Washington who won the AAAI20 Outstanding Paper Award earlier this year.

The Insights from Neuroscience and Psychology panel had researchers from other disciplines share their views on topics such as how understanding feedback in brains could help build better AI systems.

The final panel, Towards AI We Can Trust, focused on AI ethics and how to deal with biases in ML systems. Algorithmic bias is not only problematic for the direct harms it causes, but also for the cascading harms of how it impacts human beliefs, says Celeste Kidd, a professor at UC Berkeley whose lab studies how humans form beliefs and build knowledge in the world.

Unethical AI systems are problematic because they can be embedded seamlessly in peoples everyday lives and drive human beliefs in sometimes destructive and likely irreparable ways, Kidd explains. The point here is that biases in AI systems reinforce and strengthen biases in the people who use them.

Kidd says right now is a terrifying time for ethics in AI, especially with the termination of Timnit Gebru from Google. She says its clear that private interests will not support diversity, equity and inclusion. It should horrify us that the control of algorithms that drive so much of our lives remains in the hands of a homogeneous narrow-minded minority.

Margaret Mitchell, Gebrus co-lead at Googles Ethical AI team and one of the co-authors of the paper at the centre of the Gebru controversy, introduced research she and Gebru were working on. One of the key things we were really trying to push forward in the ethical AI space is the role of foresight, and how that can be incorporated into all aspects of development.

Theres no such thing as neutrality in algorithms or apolitical programming, Mitchell says. Human biases and different value judgements are everywhere from training data to system structure, post-processing steps, and model output. We were trying to break the system we call it bias laundering. One of the fundamental parts of developing AI ethically is to make sure that from the start there is a diversity of perspectives and background at the table.

This point is reflected in the format selected for this years AI Debate, which was designed to bring in different perspectives. As an old African proverb goes it takes a village to raise a child. Marcus says it similarly would take a village to raise an AI thats ethical, robust, and trustworthy. He concludes that it was great to have some pieces of that village gather together at this years AI Debate, and that he also sees a lot of convergence in what the panellists brought to the event.

Reporter: Yuan Yuan | Editor: Michael Sarazen

Synced Report |A Survey of Chinas Artificial Intelligence Solutions in Response to the COVID-19 Pandemic 87 Case Studies from 700+ AI Vendors

This report offers a look at how China has leveraged artificial intelligence technologies in the battle against COVID-19. It is also available onAmazon Kindle.Along with this report, we also introduced adatabasecovering additional 1428 artificial intelligence solutions from 12 pandemic scenarios.

Clickhereto find more reports from us.

We know you dont want to miss any news or research breakthroughs.Subscribe to our popular newsletterSynced Global AI Weeklyto get weekly AI updates.

Like Loading...

Read more:
'The Debate of the Next Decade' AI Debate 2 Explores AGI and AI Ethics - Synced

Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program – Business Wire

INGELHEIM, Germany & OCHSENHAUSEN, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced the execution of the agreement on the acquisition of Labor Dr. Merk & Kollegen. The acquisition will enable Boehringer Ingelheim to further expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology therapies including the Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP) platform and cancer vaccines platforms. Labor Dr. Merk & Kollegen has outstanding experience in process development, manufacturing and analytical characterization in virology besides expertise in microbiology and cell culture. Labor Dr. Merk & Kollegen has already worked in close collaboration with Boehringer Ingelheim on viral-based therapy development since 2015.

The acquisition of Labor Dr. Merk & Kollegen is strengthening our promising pipeline with diverse potential first-in-class cancer immunology and cancer cell directed therapies for patients with hard-to-treat cancer, said Dr. Michel Pairet, member of Boehringer Ingelheims Board of Managing Directors with responsibility for the companys Innovation Unit. The trusting and highly effective collaboration between our scientists and the Labor Dr. Merk & Kollegen team has already contributed significantly to our progress in viral-based cancer therapies. We will welcome the Labor Dr. Merk & Kollegen team and look forward to jointly advancing our program in this area.

Boehringer Ingelheim is taking cancer on by strengthening its position in cancer immunology, with a focus on cancer vaccines, oncolytic viruses, T-cell engagers, stromal modulators and myeloid cell modulators by combining its world-class, in-house research and development with that of highly innovative external companies. The addition of Labor Dr. Merk & Kollegens site will enable Boehringer Ingelheim to further strengthen its oncolytic virus and cancer vaccine development capabilities and capacities by establishing an end-to-end fully integrated center of excellence for virus development and clinical manufacturing. It will add to a series of strategic acquisitions and collaborations over the past years, including the acquisition of ViraTherapeutics and AMAL Therapeutics, which are contributing assets that will be further developed at Labor Dr. Merk & Kollegens site.

Labor Dr. Merk & Kollegen is a privately-held company founded in 1971. It is headquartered in Ochsenhausen, Germany, close to Boehringer Ingelheims Biberach R&D site. As a center of excellence in virology, Labor Dr. Merk & Kollegen has a long track record in GLP and GMP certified biosafety testing. In recent years Labor Dr. Merk & Kollegen established its GMP-virus manufacturing facility. With around 130 highly qualified and specialized employees, the company has built considerable expertise in process development, manufacturing and analytical characterization of viral therapeutics and oncolytic viral therapeutics. Labor Dr. Merk & Kollegen will be integrated with all employees as a new unit into Boehringer Ingelheims Development organization and continue to operate at its Ochsenhausen site. A future expansion is planned.

Following our successful strategic partnership, we are really excited to join forces with Boehringer Ingelheim, said Dr. Ingrid Rapp, CEO at Labor Dr. Merk & Kollegen. Boehringer Ingelheim is a truly global pharmaceutical company with excellent R&D capacities. We look forward to taking our next development step in oncology as part of this outstanding team.

The companies did not disclose the financial terms of the deal. The transaction is subject to the approval of the competition authorities in Germany. Closing will follow thereafter.

Please click on the following link for Notes to Editors:

http://www.boehringer-ingelheim.com/press-release/agreement-acquire-labor-dr-merk

See original here:
Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program - Business Wire

Silicon Therapeutics Announces Members of Scientific Advisory Board – Business Wire

BOSTON--(BUSINESS WIRE)--Silicon Therapeutics, a privately-held, integrated therapeutics company with a pioneering drug discovery platform based on physics-driven molecular simulations, today announced the members of the Silicon Therapeutics scientific advisory board (SAB), which include Dr. Elliot L. Chaikof, Dr. Timothy P. Heffernan, Dr. Sun Hur, Dr. Pasi A. Jnne and Dr. Lijun Sun.

The Silicon Therapeutics SAB is comprised of experts in biophysics, medicinal chemistry, translational medicine and research and development (R&D) in oncology and immunology. These experts will serve as a strategic resource for Silicon Therapeutics to provide scientific review and high-level advice about the companys drug discovery strategy as it continues to advance the companys therapeutic pipeline using its proprietary simulation platform.

We are honored to officially welcome Drs. Chaikof, Heffernan, Hur, Jnne and Sun as members of our SAB, said Christopher Winter, Ph.D., chief of research and development. Each members expertise, insights and direction will provide a tremendous knowledge base that will help inform our approach regarding research and clinical development activities, which will be invaluable as we head into the next phase of our growth advancing our in-house research programs developed utilizing our proprietary drug discovery platform.

The SAB will be involved in strategic discussions related to targets, research and pre-clinical development, as well as the next generation, first-in-class therapeutic pipeline.

Silicon Therapeutics is focused on the discovery and development of first-in-class small molecules targeting key drivers of disease in cancer and inflammation that have proven difficult to treat with prior approaches and thus previously considered undruggable. The companys unique discovery platform is fully integrated with Silicon Therapeutics internal laboratories using cutting edge experimental capabilities in biophysics, biology and chemistry.

ABOUT THE SILICON THERAPEUTICS SCIENTIFIC ADVISORY BOARD

Elliot L. Chaikof, M.D., Ph.D. is a co-founder of Silicon Therapeutics and chair of the Roberta and Stephen R. Weiner department of surgery and surgeon-in-chief at the Beth Israel Deaconess Medical Center (BIDMC), as well as the Johnson & Johnson professor of surgery at Harvard Medical School in Boston. Dr. Chaikof is a member of the Wyss Institute of Biologically Inspired Engineering of Harvard University and the Harvard Stem Cell Institute, also in Boston.

Dr. Chaikof earned a bachelor of arts degree and medical doctor degree from Johns Hopkins University in Baltimore and a doctor of philosophy degree in chemical engineering from the Massachusetts Institute of Technology in Boston, where he focused on the design of artificial organs. Dr. Chaikof completed his training in general surgery at the Massachusetts General Hospital in Boston and in vascular surgery at Emory University School of Medicine in Atlanta.

Timothy P. Heffernan, Ph.D. is head of oncology research within the division of therapeutics discovery and development at The University of Texas MD Anderson Cancer Center in Houston. Dr. Heffernan also serves as executive director for the Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) platform, a translational research unit focused on accelerating the pre-clinical evaluation of novel drugs to inform innovative clinical trials.

Dr. Heffernan earned a doctor of philosophy degree in cell and molecular pathology from the University of North Carolina at Chapel Hill in Chapel Hill, N.C. and performed his postdoctoral training at the Dana-Farber Cancer Institute and Harvard Medical School in Boston.

Sun Hur, Ph.D. is an Oscar M. Schloss professor in the department of biological chemistry and molecular pharmacology in the department of pediatrics at Harvard Medical School in Boston.

Dr. Hur earned a bachelor of science degree in physics from Ewha Womans University in Seoul, South Korea and a doctor of philosophy degree in physical chemistry with Dr. Thomas C. Bruice at the University of California, Santa Barbara. Dr. Hur did her post-doctoral work in x-ray crystallography with Dr. Robert M. Stroud at the University of California, San Francisco. She joined Harvard Medical School in 2008 as an assistant professor and became affiliated with Boston Childrens Hospital in 2010.

Pasi A. Jnne, M.D., Ph.D. is a thoracic medical oncologist at the Dana-Farber Cancer Institute, a professor at Harvard Medical School, director of the Lowe Center for Thoracic Oncology and director of the Belfer Center for Applied Cancer Science in Boston.

Dr. Jnne earned a medical doctor degree and doctor of philosophy degree at the University of Pennsylvania in Philadelphia. He completed postgraduate training in internal medicine at Brigham and Womens Hospital and in medical oncology at Dana-Farber Cancer Institute in Boston.

Lijun Sun, Ph.D. is a co-founder of Silicon Therapeutics and an associate professor of surgery at Harvard Medical School, Beth Israel Deaconess Medical Center in Boston.

Dr. Sun earned a doctor of philosophy degree in organic chemistry from Emory University in Atlanta and completed postdoctoral training in biomaterial research at Emory School of Medicine in Atlanta.

ABOUT SILICON THERAPEUTICS

Silicon Therapeutics is a privately held, fully integrated drug design and development company focused on small molecule therapeutics. The Silicon Therapeutics proprietary physics-driven drug design platform combines quantum physics, statistical thermodynamics, molecular simulations, a dedicated HPC super-computing cluster, purpose-built software, in-house laboratories and clinical development capabilities. The platform was built from the ground up to address difficult targets using physics-based simulations and experiments to pioneer a new path for drug design with the prime goal of delivering novel medicines to improve the lives of patients.

Silicon Therapeutics is currently the only company that owns the entire spectrum of proprietary physics-driven drug discovery from chip-to-clinic. The companys lead program is a highly differentiated small molecule Stimulator of Interferon Genes (STING) agonist for the treatment of cancer, which entered the clinic in November 2020. The companys headquarters are located in Boston. To learn more about Silicon Therapeutics, please visit our website at http://www.silicontx.com or follow us on LinkedIn and Twitter.

Excerpt from:
Silicon Therapeutics Announces Members of Scientific Advisory Board - Business Wire

Aural Analytics, Inc. Announces the Launch of a Large-Scale Pivotal Study for Its Respiratory and Speech Motor Control Prediction Software Tools -…

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Aural Analytics, Inc., the industry leader in speech neuroscience and speech analytics technologies, announced today the initiation of a multi-product pivotal study to demonstrate the safety and efficacy of its speech-based tools for measuring pulmonary function and speech motor function in amyotrophic lateral sclerosis (ALS). The company anticipates submitting the results of this multi-site, multi-language, 280 participant, prospective, blinded study to the U.S. Food and Drug Administration (FDA) in late 2021. The study, conducted as part of the Target ALS Diagnosis Initiative, is one of several pivotal studies Aural Analytics is set to kick off in 2021 as it expands its suite of clinical-grade speech-based digital tools.

The Aural Analytics VCP software tool enables on-demand, real-time objective evaluation of pulmonary function by predicting forced vital capacity (FVC) and forced expiratory volume (FEV1) without the need for specialized hardware in-clinic and at-home. These measurements are commonly used in the assessment of airflow obstruction (COPD, asthma) and restrictive lung disease (ALS). The VCP software is currently being used as one approach to screen for eligibility in the Healey Center ALS platform trial at Massachusetts General Hospital. Aural Analytics will also use the study to further demonstrate the safety and efficacy of its speech-based assessment software that enables on-demand, real-time objective monitoring of symptoms and progression in diseases known to impact bulbar function (speech and swallowing).

Aural Analytics is enabling clinical-grade speech analytics in areas of critical unmet patient and clinical need. This study will be the basis of multiple regulatory submissions for products that have broad clinical utility and commercial pathways, said Daniel Jones, co-founder and CEO of Aural Analytics. We continue to work closely with regulators at the FDA and key stakeholders across the healthcare industry to ensure safe, reliable, repeatable and transparent speech-based tools are brought to market.

More about the Aural Analytics VCP Software in ALS

Respiratory failure is the leading cause of death in patients with ALS. As a result, regular assessment of respiratory function is the standard of care. People with ALS often have problems achieving valid measures on standard in-clinic or at-home spirometers. Lip weakness can prevent creation of a tight seal around the spirometer and some with ALS experience an involuntary slamming shut of their vocal cords when they exhale forcefully. Spirometers often induce bouts of coughing which, given the COVID-19 pandemic, has made it increasingly difficult to objectively measure respiratory function in-clinic. Our VCP software is designed to tap into both inspiratory and expiratory muscle strength, without requiring lip strength, and with far less chance of inducing laryngospasm or coughing, said Dr. Julie Liss, co-founder and chief clinical officer at Aural Analytics. Our application enables a patient to easily deliver pulmonary function data, remotely, with just a few short tasks. The outcome measures are clinically relevant, interpretable, reliable and highly repeatable.

More about the Aural Analytics Speech Motor Control Software

Functional rating scales have been used historically to capture the impact of disease on a person's daily life. These rating scales are often coarse, subjective, and can miss key information about how a patient is doing. We have found that the information we extract from speech samples tracks well with a number of functional rating scales for different diseases, said Dr. Liss. Yet, more importantly, our speech metrics can detect changes in disease before they have functional consequences and in a far more frequent, objective way. We believe this tool will provide an opportunity for greater precision in clinical management.

The Aural Analytics VCP and speech motor assessment applications further add to the companys technology suite which includes mobile applications currently available for use in clinical research and clinical settings, an embeddable mobile and web SDK, web-progressive applications, and APIs, all with cloud-based computation that power disease-specific speech tasks and analytics.

About Aural Analytics, Inc.

Aural Analytics is the industrys leading speech neuroscience company building the worlds most advanced clinical-grade speech analytics platform for health applications across the lifespan. Its suite of mobile-first, patient-centric applications, available in up to 30 languages across Android, iOS and the web are easy to use, secure, and provide robust, clinically relevant, interpretable and validated metrics reflecting the neurological and respiratory health of its users. The company is founded on nearly three decades of NIH and NSF-funded research in speech neuroscience, is backed by dozens of high-caliber scientific publications, and has won several awards for its work in the field, including the prestigious Global SCRIP Award for Best Technology Development in Clinical Trials. Aural Analytics is based in Scottsdale, AZ. For more information, please visit auralanalytics.com or follow Aural Analytics on Twitter, LinkedIn, Medium and Facebook.

About Target ALS

Target ALS is a 501(c)(3) medical research foundation committed to the search for effective treatments for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrigs disease. We envision a world in which no one dies of ALS and play a unique role in the battle against this disease. Founded in 2013 by former New York City deputy mayor Dan Doctoroff who lost both his father and uncle to ALS our approach is breaking down barriers and silos that previously inhibited research results. We do this through our Target ALS Innovation Ecosystem, which facilitates unparalleled collaboration between researchers from academia and the pharma/biotech industry. The Target ALS Innovation Ecosystem has revolutionized the field in just seven years through collaborations that have resulted in the first potential treatments since ALS was identified in 1869.

To date, the Target ALS Innovation Ecosystem, which launched in 2013 and set the groundwork for the new Target ALS Diagnosis Initiative, has yielded 175+ research projects, 12+ therapeutic targets and five clinical trials, to date.

About The Target ALS Diagnosis Initiative

Target ALS launched the first-ever comprehensive effort to discover ALS biomarkers The Target ALS Diagnosis Initiative through which the organization will invest $15 million in collaborative grantmaking and the development of new scientific resources. The initiative was developed in response to input from over 100 scientists, patients, caregivers and other thought leaders. They universally identified ALS biomarkers as a critical unmet need to diagnose the disease early, track its progression and provide reliable measures for new treatments.

The Target ALS Diagnosis Initiative strategically focuses on three promising areas:

See the article here:
Aural Analytics, Inc. Announces the Launch of a Large-Scale Pivotal Study for Its Respiratory and Speech Motor Control Prediction Software Tools -...

Bateman, Diamond, Hultgren named to National Academy of Inventors – Washington University School of Medicine in St. Louis

Visit the News Hub

School of Medicine scientists honored for innovation

Washington University School of Medicine in St. Louis faculty members (left to right) Randall J. Bateman, MD, Michael S. Diamond, MD, PhD, and Scott Hultgren, PhD, have been elected fellows of the National Academy of Inventors.

Neurologist Randall J. Bateman, MD, virologist and immunologist Michael S. Diamond, MD, PhD, and microbiologist Scott Hultgren, PhD all faculty members at Washington University School of Medicine in St. Louis have been named fellows of the National Academy of Inventors, the highest professional distinction accorded solely to academic inventors.

They are among 175 new fellows elected this year in recognition of their innovation in creating and facilitating outstanding inventions that have made a tangible impact on quality of life, economic development and the welfare of society. They will be honored at a ceremony during the academys annual meeting in June in Tampa, Fla.

Randall J. Bateman

Bateman, the Charles F. and Joanne Knight Distinguished Professor of Neurology, is being recognized for his pioneering work in diagnostics and clinical treatment for Alzheimers disease. His research into techniques to detect molecular signs of Alzheimers has led to the first blood test approved under the Clinical Laboratory Improvement Amendments (CLIA), to aid in the diagnosis of Alzheimers. The aim of the CLIA program, under the Centers for Medicare & Medicaid Services, is to ensure quality laboratory testing in people. The Alzheimers test, made by the startup company C2N Diagnostics, became available to patients and physicians in October.

Bateman co-founded C2N in 2007 with David Holtzman, MD, the Andrew B. and Gretchen P. Jones Professor and head of theDepartment of Neurology, to provide a technology the two had developed called SILK, or stable isotope labeling kinetics. The technology measures the breakdown and synthesis rates of neurological proteins important in Alzheimers disease, such as amyloid beta, tau and others, data that can be crucial for evaluating the effectiveness of potential Alzheimers drugs. Multiple large pharma companies have partnered with C2N to use SILK to help assess drugs in clinical development.

More recently, Bateman has focused on developing sensitive techniques for detecting Alzheimers proteins in blood. The approved blood test is based on identifying the presence of amyloid beta, but he also is working on a promising blood test for tau.

Bateman earned his bachelors degree at Washington University in 1996, and his medical degree at Case Western Reserve University School of Medicine in Cleveland in 2000. He completed his residency at Barnes-Jewish Hospital and a clinical fellowship at Washington University School of Medicine before joining the faculty in 2005.

His many honors include the Chancellors Award for Innovation and Entrepreneurship, the MetLife Award in Medical Research and the Potamkin Prize for Research in Picks, Alzheimers, and Related Diseases, an international recognition sometimes referred to as the Nobel Prize for Alzheimers research. He is an elected fellow of the National Academy of Medicine.

Michael S. Diamond

Diamond, the Herbert S. Gasser Professor of Medicine, a professor of molecular microbiology, and of pathology and immunology, is being recognized for his accomplishments developing research tools and drug and vaccine candidates for emerging viruses such as West Nile, dengue, chikungunya, Zika and SARS-CoV-2, the virus that causes COVID-19.

Most recently, Diamond developed research tools to aid the international search for treatments and preventives for COVID-19, including a mouse model for COVID-19. He helped identify antibodies that are undergoing clinical testing as potential drugs for COVID-19, and developed two vaccine candidates that have shown promise in animal studies, one of which soon will be the focus of a vaccine trial in people.

During the Zika epidemic, Diamond helped develop the first mouse model and the first pregnant mouse model of Zika infection, enabling research into the devastating neurological damage seen in the fetuses of infected pregnant women. He conducted pivotal preclinical studies to advance a Zika vaccine, and identified antibodies against Zika virus that led to two novel diagnostic tests to detect Zika virus in patients.

Diamond earned his medical and doctoral degrees from Harvard in 1994. After completing a research fellowship in molecular and cell biology at the University of California, Berkeley, Diamond moved to the University of California, San Francisco, where he completed his residency in internal medicine and a clinical fellowship in infectious diseases. He returned to Berkeley to complete another research fellowship in infectious diseases in 2001, before joining Washington University School of Medicine that year.

Diamond is an elected fellow or member of the American Association for the Advancement of Science, the American Society for Clinical Investigation, the American Academy of Microbiology, the Association of American Physicians and the National Academy of Medicine.

Scott Hultgren

Hultgren, the Helen L. Stoever Professor of Molecular Microbiology, is being recognized for his pioneering research in nonantibiotic treatments and preventives for urinary tract infections (UTIs), one of the most common infections in women.

Current therapies use antibiotics to kill bacteria in the urinary tract, but they are often ineffective and can promote drug resistance. Hultgren discovered bacterial and host mechanisms that determine the onset, course and outcome of UTIs, including discovering how E. coli bacteria evade the immune system and form stable, protected bacterial communities known as biofilms. This work has led to the identification of alternative therapies based on preventing bacteria from causing disease without killing them, such as compounds that target bacterial attachment to human tissues. His work also has led to an investigational vaccine that has completed phase 1a/1b clinical trials and has been allowed by the U.S. Food and Drug Administration (FDA) for compassionate use in patients with multidrug-resistant UTI caused by E. coli.

Hultgren co-founded Fimbrion Therapeutics, which is developing decoy sugars known as mannosides as nonlethal antimicrobials to eliminate bacteria from the urinary tract. These compounds are in phase 1 clinical trials. He is also a cofounder of Quretech Bio, which is working to develop first-line drugs to combat infectious diseases and prevent antibiotic resistance.

Hultgren earned his doctoral degree from Northwestern University in 1987 before moving to Sweden to do postdoctoral research under Staffan Normark, PhD, at the University of Ume. Normark joined Washington University as head of the molecular microbiology department in 1989 and recruited Hultgren to join the faculty later that same year.

Hultgren holds 22 U.S. patents and has four pending patent applications. His many honors and awards include the Eli Lilly Microbiology Award and election to the National Academy of Medicine, the National Academy of Sciences and the American Association for the Advancement of Science.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Read the original post:
Bateman, Diamond, Hultgren named to National Academy of Inventors - Washington University School of Medicine in St. Louis

Leading Into An IPO, Airbnb Ranks #1 in Travel for Innovation, Creativity and Relevance According to Harte Hanks Behavioral Index – PRNewswire

PHILADELPHIA, Dec. 8, 2020 /PRNewswire/ --Despite the challenges related to COVID-19 that have severely impacted the hotel and travel industries, new research from the Harte Hanks Behavioral Index (HHBI) reveals that global home-sharing provider Airbnb is outperforming many leading hotel companies in key areas critical to building and maintaining long-term consumer loyalty and market share.

According to findings from the fourth wave of the Index, Airbnb, which is gearing up for its public debut this week, is outperforming traditional hotel companies in multiple areas measured by the HHBI, including Innovation, Creativity and Relevance, where it ranks first among all hospitality providers. Airbnb's performance in these areas is contributing significantly to their ability to grow their share of the hospitality marketplace.

The Harte Hanks Behavioral Index, which has been tracking consumer insights since the early stages of the pandemic, defines Innovation as being the first company in an industry to bring new innovations to the world; Creativity as helping consumers look at the world differently; and Relevance as a company's ability to understand and respond to what's happening in a culture.

"Airbnb overshadows traditional hotels by creating a personal experience that starts at the moment of your booking and lasts throughout your stay. Their hosts provide everything from customized restaurant recommendations to tips on the best local farmer's markets. That is meaningful personalization," says Gretchen Ramsey, Chief Strategy Officerat Harte Hanks. The secret to Airbnb's success may be in how they respond to behavioral needs. "Travelers now expect health and safety measures to follow the highest of standards and more than anything want financial protections built into their bookings. What the pandemic taught the traveler was to be more cautious about the small print, so transparency and financial innovation will be the trends going forward."

In addition to its strong performance in the areas of Innovation, Creativity and Relevance, Airbnb also scored highly in the category of a brand that consumers would consider in the future, ranking third just behind Marriott (#1) and Hilton (#2). In terms of travel brands that consumers would recommend, the top ten in order were Marriott, Hilton, Hyatt, Comfort Suites, Airbnb, Hard Rock, Intercontinental, Wyndham, Atlantis, and Wynn.

Interestingly, the HHBI revealed that no lodging provider measured scored highly across the attributes of Purpose, Authenticity and Responsiveness areas where major hotel brands have a lot of natural equity, but they're not getting credit for it. Hotel brands must make sure they leverage their legacy to ensure they are delivering on modern travelers' expectations. "Health and safety measures are expected in today's world. And "loyalty" through points programs is no longer relevant what travelers want to know is how your brand will make them feel."

According to Ramsey, we are living today in an "Epiphany Economy," where it's not enough to provide a product or service; brands must also demonstrate empathy and deliver meaningful action against consumer and cultural needs.

"For example, traditional hotel brands should double down on their founders' set of values, whether about caring for the guest, providing an upscale experience, or delivering against surprise and delight," says Ramsey. "They need to give travelers a customized experience, not just in terms of choosing a foam pillow over feathers but being able to express their travel occasion and having the hotel respond with appropriate options/upgrades."

TheHarteHanksBehavioral Index isaglobal initiative conducted on a quarterly basis to uncover emerging behavioral shifts that influence consumer behavior. The ultimate goal is to help brands understand how to best meet their consumers' needs.

The Index was developed using a proprietary method that evaluates brands on a set of criteria, such as Empathy and Action both ways to serve consumers.The latest wave is based on 700 million global social conversations with 11,000 people surveyed, 40,000 global stories and 2 million semantic artifacts.

View the webinar here, or for information on how to apply these learnings to your travel brand, please email [emailprotected].

About Harte Hanks:

Harte Hanks is a behavior-driven Customer Experience (CX) company uniquely able to partner with brands on everything from data to delivery. We marry our data-driven understanding of human behavior with a seamless connection to the consumer through a full suite of digital, direct marketing and eCommerce services, including fulfillment and customer care. Harte Hanks works with leading Fortune 500 companies, including Bank of America, BMW Group, Cisco, L'Oral S.A., Pfizer, Sony and Unilever. Headquartered inPhiladelphia, PA, Harte Hanks has more than 2,000 employees throughoutNorth America,Asia-PacificandEurope. For more information, visit Harte Hanks at hartehanks.com.

SOURCE Harte Hanks

https://www.hartehanks.com

Read more from the original source:
Leading Into An IPO, Airbnb Ranks #1 in Travel for Innovation, Creativity and Relevance According to Harte Hanks Behavioral Index - PRNewswire

Will robots ever be in charge? Not if we raise them well – Innovation Origins

According to the Israeli historian-futurologist Yuval Noah Harari, humans are becoming more and more robotic and robots are increasingly gaining human traits. Over the past few months, Innovation Origins has been looking around the Dutch robotics nursery at Eindhoven University of Technology (TU/e) and wrote about it in this series. Today, the last installment.

A 3D printer that builds your home exactly the way you want it. All parts are movable so that the house can literally be adjusted to your liking. An extra-large living room or balcony, that can be arranged right away. A robot brings you a cup of coffee even before you realize that you feel like one. And if you need care at a later stage of your life, the robot will always be by your side. Are you already able to envisage this in your future?

It is obvious, robots are going to change our lives. Nowadays, you can develop a robot for every application in every field. For this series, scientists spent hours talking about the technology, potential fields of application, and the ethical aspects of (self-steering) robots. All these robots and related research have one thing in common: Robots have to respond to the behavior of people and, moreover, behave more and more like human beings themselves.

The technology that is behind it all? Artificial intelligence. This is the basis for all robots, the brain, you might say. A great intangible thing that will overtake humanity if we are not careful enough. Because, just how human can robots become? How clever will they become? And how will they learn to deal with emotions?

There is so much that can be done and yet at the same time, not so much either. The soccer robots from Tech United are getting better every year. But they still have a long way to go if they want to beat the human world champions. Robots do not have any insight that enables them to predict what will happen in a few seconds. Something that is extremely important in soccer. This is difficult to pinpoint in an algorithm.

Predictive capability is also important in the development of autonomous cars. As humans, we often see, for example, when a cyclist is going to turn even before they signal that with a hand gesture. But what do we base that on? It is difficult to establish rules for this that an algorithm can use. The robots have to learn from a wealth of data about the choices people make in these kinds of situations. That takes time. For now, therefore, AI cannot match a human driver by a long shot.

But there are also tasks that robots can perform much better than humans. Order picking, for example. But even this type of robot is not yet ready for the world of humans. A robot cannot feel the difference between materials. This means that it does not know how to handle certain materials. When people pack a box of items, they know exactly which materials they can press down a bit more so that they can close the box. A robot does not have that insight. Such skills are needed to really be able to function as, for example, a fully-fledged employee in a factory.

And we have not even mentioned service robots in healthcare yet. A robot can perform tasks such as lifting someone out of bed, bringing food, or helping them to the bathroom, although interacting with people is still very complicated. How hard do you have to grab someone when you are helping them to go to the toilet? A person needs to feel safe and of course, you should not drop them either, but grasping them too hard is painful. The robot itself has no skin, has no idea what it feels like, and thus has difficulty assessing this kind of thing. Moreover, this varies from person to person. There are several service robots under development at the moment. It is often the case that these can only perform a few specific tasks. As such, the full range of tasks of a nurse is (still) far too complex.

Robots need to understand their environment in order to truly become part of society. They have to recognize situations and be able to respond to them accordingly. Scientists are attempting to put the social behavior of human beings into a robot. But this is tricky. After all, robots work on the basis of facts and connections. But human feelings cannot be grasped that way. How close do you stand to someone when you are having a conversation with them? How do you know that someone has heard you when you say something? And how do you identify feelings someone else might have? All things that we use feelings and emotions in order to work out. Which is quite hard to explain to a computer.

An algorithm can learn from mistakes. But then it needs to know what is right and what is wrong. Except that so many things in society are not so black and white. Every situation is slightly different, which is what makes it all so complicated. You could compare it to a childs learning process. From the first weeks of their lives, children learn more and more about the world around them. They discover basic principles such as gravity by doing things. Social skills also develop over time. Robots are undergoing that same kind of development too. The university is not just a nursery, it is also a preschool for robots.

The fact that robots are still in preschool feels reassuring for now: It means that people are still not replaceable. We are creative, have empathy and emotions. Robots do not have any of those qualities. Not yet, at least. Because, how sensitive could a robot actually become? What if they develop emotions as well? Will we be able to distinguish people from robots in the future? These are questions that remain unanswered. The future will teach us.

This is just the tip of the iceberg. There is still a tremendous treasure trove of technological developments, new applications, and special innovations lying beneath the surface. We will discover them in time. In the interim, scientists are continually developing existing robots. What if the robots start puberty soon? The researchers are preparing themselves for real issues to do with their upbringing. After all, humankind is in charge of robots and their development. At least for the time being. Will robots ever take over the world? Maybe in the future, but right now, humans and robots are empowering each other.

Read all articles in this series here.

Read more from the original source:
Will robots ever be in charge? Not if we raise them well - Innovation Origins

Life Science Ontario Announces Recipients of the 2021 LSO Awards – Business Wire

TORONTO--(BUSINESS WIRE)--LSO today announced the recipients of its 2021 LSO Awards, recognizing outstanding individuals and companies contributing to the success of Ontarios life sciences sector. The awards will be presented during LSOs Celebration of Success Awards in February 2021.

The 2021 awardees are as follows:

The LSO Awards are an important part of the organizations mandate to advocate for Ontarios life sciences sector, by celebrating the individuals and companies behind its success.

2020 has been a difficult year for everyone; but COVID-19 has also highlighted the amazing contributions of the life sciences sector to solving some of societies largest challenges, said LSO President and CEO Dr. Jason Field. LSOs awards recognize these contributions annually and this years award recipients represent the many diverse ways our sector impacts the everyday lives of Canadians and the world in which we live through science, innovation and leadership.

To explore sponsorship opportunities, contact: admin@lifesciencesontario.ca

Biographies

Michael Julius, Former Vice President, Research at Sunnybrook Health Sciences CentreLifetime Achievement Award

Dr. Michael Julius is past Vice President, Research at Sunnybrook Health Sciences Centre (2000-2020). He created an international hub for life sciences dedicated to both discovery and commercialization. This initiative achieved a functional integration of researchers, clinicians, business and patients towards moving discoveries through the marketplace and into the clinic. He shepherded growth to a $125M annual research enterprise which spun off 15 companies over his tenure. Michael is currently partnering in the launch of a life sciences capital management fund.

Ahead of taking on his leadership position at Sunnybrook, Michael Chaired the Department of Immunology at the University of Toronto (1994-2000). He has Chaired both the Canadian Institutes for Health Research review panel for Immunology and Transplantation and Research Canada, an advocacy corporation dedicated to ensuring that the federal government supports and funds the priority of health research in Canada. He serves as a member of Scientific Advisory Boards for a number of companies and has Chaired two of Sunnybrooks spin-off companies.

Michael completed his undergraduate degree in genetics at McGill University and his doctoral work in genetics and immunology at Stanford University. Michael was recruited to the Basel Institute for Immunology supported by Hoffman La Roche, where he remained for the 13 years.

Having published over 200 research papers and reviews in his area of expertise, many of which have achieved citation records, Michael has in-depth knowledge of multiple therapeutic areas, including neuroscience, cancer, cardiovascular and immune system; and expertise across multiple platforms, including high content cellular analyses, AI, health informatics, and imaging-guided interventions and therapeutics.

Eugenia Duodu, CEO, Visions of Science Network for LearningCommunity Service Award

Eugenia Duodu is the CEO of Visions of Science Network for Learning (www.vosnl.org), a charitable organization that empowers youth from low-income communities through meaningful engagement in STEM (science, technology, engineering and math). She is an educator, speaker, community organizer and advocate who is passionate about creating equitable opportunities for youth to achieve their full potential. Eugenia Duodu holds both an honours bachelor degree in Chemistry and Biology and a PhD in Chemistry from the University of Toronto.

Anne Woods, Managing Director of Life Sciences and Healthcare, Silicon Valley BankVolunteer Award

Anne Woods is the managing director of the Life Science and Healthcare practice for Silicon Valley Bank in Toronto where she is responsible for leading the banks efforts in this sector across Canada.

Anne has close to 25 years experience in capital markets and life sciences. She began her career as a financial analyst and in 2005, went back to her roots in life sciences. Prior to joining SVB, Anne spent several years as a director with The Pangaea Group bringing insights and strategic direction to life science and healthcare clients.

In 2018, Anne joined the board of Life Sciences Ontario. She holds a BSc from McGill University, a MA from the University of Guelph and is a CFA Charterholder.

VIVE Crop Protection Inc.Life Sciences Company of the Year

Vive Crop Protection creates Precision Chemistry to expand the horizons of Precision Agriculture. Vive products are built on the patented Allosperse Delivery System, which greatly improves the targeting and performance of chemical and biological active ingredients, helping growers achieve real results. Vive Crop Protection commercially launched in 2016 and currently has five unique products available in the US market, with two more awaiting US EPA registration and one awaiting Canadian PMRA registration.

Vive anticipates launching the first-ever combination chemical/biological fungicide product in spring 2021 to US sugarbeet and corn growers. Its head office is in Mississauga and employs nearly 30 chemists, biologists and other professionals.

John Kelly, Deputy Minister, Ontario Ministry of Agriculture, Food and Rural AffairsLSO Leadership Award

Dr. John Kelly currently serves as Deputy Minister for the Ontario Ministry of Agriculture, Food and Rural Affairs. He was recently Chief Innovation Officer for Bioenterprise Corporation. Dr. Kelly has an extensive background working with entrepreneurs and innovation in human health and life sciences, agriculture, food and bio-economy sectors in domestic and international markets, with focus on innovation development and implementation, actively advancing products and technologies. An extensive publisher, he has authored hundreds of research and extension publications throughout his career, attracted several million dollars in investment and been a serial entrepreneur and investor. He has a wealth of experience in the private and public sector and has held various executive positions with start-ups, venture capital, multinational companies and not-for-profits, including KeliRo Company Inc., Bioenterprise Capital, DNAstack, KiKi Maple Water, Ontario Fruit & Vegetable Growers Association, MaRS Landing, Land OLakes, Rhone-Poulenc Canada Inc. and Aventis CropSciences Inc. He has also served on numerous Board of Director appointments including with Life Sciences Ontario, Canada Foundation for Innovation, Ontario Genomics, Ontario Hazelnut Association, Ontario Lavender Association and others. Dr. Kelly holds a B.Sc. (Agr). and Ph.D. from the University of Guelph and a Master of Science from the University of Alberta. He has also held Adjunct Professorships in the Department of Animal Biosciences and the Department of Plant Agriculture at the University of Guelph.

ABOUT LIFE SCIENCES ONTARIO (LSO)

Life Sciences Ontario (LSO) is a member-funded, not-for-profit organization with a legacy of more than 30 years advancing the success of Ontarios life sciences sector. LSO collaborates with government, academia, industry, and other life sciences organizations in Ontario and across Canada to promote and encourage commercial success throughout the sector. The organization provides a wide range of networking and educational events and operates a mentorship program that is helping to develop highly skilled talent and build new business opportunities for the life sciences sector. In addition, LSO launched the Life Sciences Ontario Scholarship Program, the program awards students financial benefits and an opportunity to connect with a professional from the life sciences sector. LSO is an effective conduit for delivering policy options to governments, and its dedicated to promoting Ontarios life sciences sector internationally. For more information, please visit https://lifesciencesontario.ca.

Continue reading here:
Life Science Ontario Announces Recipients of the 2021 LSO Awards - Business Wire

Postdoctoral Fellow in Centre for Neural Computation job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY – NTNU | 234854 – Times Higher…

About the position

We have a vacancy for a postdoctoral fellow.

The position is a part of the Kavli Institute for Systems Neuroscience/Centre for Neural Computation. The Centre for Neural Computation is a centre of excellence funded for 10 years by the Norwegian Research Council. We offer an international and multidisciplinary environment in which creativity and scientific discourse is valued and stimulated. Seehttp://www.ntnu.edu/kavliandwww.spinorkavli.orgfor detailed information.

You will reportto Professor Yasser Roudi.

Duties of the position

The successful applicant will work on analyzing statisticalproperties of texts as a collaborative project between YasserRoudi (SPINOr, Kavli Institute for Systems Neuroscience,NTNU) and Giosu Baggio (Language Acquisition andLanguage Processing Lab, Department of Language andLiterature, NTNU). The work involves applying recentlydeveloped data analysis techniques (Marsili, Mastromatteo, Roudi, 2013; Cubero et al., 2019 and 2020) to study thedistributional properties of words, collocations, and syntacticstructures in literary works and other texts, and how suchstatistics change across texts and through time.

Required selection criteria

Postdoctoral fellow:

The appointment is to be made in accordance with the regulations in force concerningState Employees and Civil Servants and national guidelines for appointment as PhD, post doctor and research assistant.

Preferred selection criteria

Personal characteristics

We offer

Salary and conditions

Postdoctoral fellowship:

The employment period is 2-4years depending on the candidate.

Postdoctoral candidates are placed in code 1352, and are normally remunerated at gross from NOK 542 400 per annum before tax, depending on qualifications and seniority. From the salary, 2% is deducted as a contribution to the Norwegian Public Service Pension Fund.

The engagement is to be made in accordance with the regulations in force concerning State Employees and Civil Servants, and the acts relating to Control of the Export of Strategic Goods, Services and Technology. Candidates who by assessment of the application and attachment are seen to conflict with the criteria in the latter law will be prohibited from recruitment to NTNU. After the appointment you must assume that there may be changes in the area of work.

The position is subject to external funding.

It is a prerequisite you can be present at and accessible to the institution daily.

About the application

The application and supporting documentation to be used as the basis for the assessment must be in English

Publications and other scientific work must follow the application. Please note that applications are only evaluated based on the information available on the application deadline. You should ensure that your application shows clearly how your skills and experience meet the criteria which are set out above.

The application must include:

Joint works will be considered. If it is difficult to identify your contribution to joint works, you must attach a brief description of your participation.

In the evaluation of which candidate is best qualified, emphasis will be placed on education, experience and personal suitability.

NTNU is committed to following evaluation criteria for research quality according toThe San Francisco Declaration on Research Assessment - DORA.

General information

Working at NTNU

A good work environment is characterized by diversity. We encourage qualified candidates to apply, regardless of their gender, functional capacity or cultural background.

The city of Trondheimis a modern European city with a rich cultural scene. Trondheim is the innovation capital of Norway with a population of 200,000. The Norwegian welfare state, including healthcare, schools, kindergartens and overall equality, is probably the best of its kind in the world. Professional subsidized day-care for children is easily available. Furthermore, Trondheim offers great opportunities for education (including international schools) and possibilities to enjoy nature, culture and family life and has low crime rates and clean air quality.

As an employeeatNTNU, you must at all times adhere to the changes that the development in the subject entails and the organizational changes that are adopted.

Information Act (Offentleglova), your name, age, position and municipality may be made public even if you have requested not to have your name entered on the list of applicants.

If you have any questions about the position, please contact: Yasser Roudi, Professor, Kavli/CNC

Email: yasser.roudi@ntnu.no

If you have any questions about the recruitment process, please contact Chief Executive Officer, Ole Kristian Indergrd, e-mail: ole.k.indergard@ntnu.no

Please submit your application electronically via jobbnorge.no with your CV, diplomas and certificates. Applications submitted elsewhere will not be considered. Diploma Supplement is required to attach for European Master Diplomas outside Norway. Chinese applicants are required to provide confirmation of Master Diploma fromChina Credentials Verification (CHSI).

If you are invited for interview you must include certified copies of transcripts and reference letters.

Application deadline: 20.12.2020

NTNU - knowledge for a better world

The Norwegian University of Science and Technology (NTNU) creates knowledge for a better world and solutions that can change everyday life.

The Kavli Institute for Systems Neuroscience is part of the Faculty of Medicine and Health Sciences at NTNU. It was established as a Centre of Excellence in 2002, and designated as a Kavli Foundation Institute in 2007 (www.kavlifoundation.org). The scientific goal of the Institute is to increase the understanding of neural circuits and systems along with their role in generating psychological functions.

Today, the Institute consists of the Centre for Neuronal Computation (CNC) as well as the Egil and Pauline Braathen and Fred Kavli Centre for Cortical Microcircuits. In 2014, the Nobel Prize in Physiology or Medicine was awarded to two of the Institutes professors, Edvard Moser and May-Britt Moser. The Institute is responsible for an international master's programme and is affiliated with a doctoral programme in medicine. Through our widespread network of international collaboration, we offer unique career opportunities. For further information, see: http://www.ntnu.edu/kavli.

Deadline20th December 2020EmployerNTNU - Norwegian University of Science and TechnologyMunicipalityTrondheimScopeFulltimeDurationFixed TermPlace of service

More here:
Postdoctoral Fellow in Centre for Neural Computation job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 234854 - Times Higher...

Symphony of Cellular Activities Revealed by Fluorescent Imaging Technique – SciTechDaily

MIT researchers have developed a way to simultaneously image up to five different molecules within a cell, by targeting glowing reporters to distinct locations inside the cell. This approach could allow scientists to learn much more about the complex signaling networks that control most cell functions. Credit: Courtesy of the researchers

Fluorescent imaging technique simultaneously captures different signal types from multiple locations in a live cell.

Within a single cell, thousands of molecules, such as proteins, ions, and other signaling molecules, work together to perform all kinds of functions absorbing nutrients, storing memories, and differentiating into specific tissues, among many others.

Deciphering these molecules, and all of their interactions, is a monumental task. Over the past 20 years, scientists have developed fluorescent reporters they can use to read out the dynamics of individual molecules within cells. However, typically only one or two such signals can be observed at a time, because a microscope cannot distinguish between many fluorescent colors.

MIT researchers have now developed a way to image up to five different molecule types at a time, by measuring each signal from random, distinct locations throughout a cell. This approach could allow scientists to learn much more about the complex signaling networks that control most cell functions, says Edward Boyden, the Y. Eva Tan Professor in Neurotechnology and a professor of biological engineering, media arts and sciences, and brain and cognitive sciences at MIT.

There are thousands of molecules encoded by the genome, and theyre interacting in ways that we dont understand. Only by watching them at the same time can we understand their relationships, says Boyden, who is also a member of MITs McGovern Institute for Brain Research and Koch Institute for Integrative Cancer Research.

In a new study, Boyden and his colleagues used this technique to identify two populations of neurons that respond to calcium signals in different ways, which may influence how they encode long-term memories, the researchers say.

Boyden is the senior author of the study, which was published on November 23, 2020, in Cell. The papers lead authors are MIT postdoc Changyang Linghu and graduate student Shannon Johnson.

Just like listening to the sound of a single instrument from an orchestra is far from enough to fully appreciate a symphony, Linghu says, by enabling observations of multiple cellular signals at the same time, our technology will help us understand the symphony of cellular activities. These four images compare various ways scientists make molecular activity visible, with the new technique on the bottom right. Credit: Courtesy of the researchers. Edited by MIT News

To make molecular activity visible within a cell, scientists typically create reporters by fusing a protein that senses a target molecule to a protein that glows. This is similar to how a smoke detector will sense smoke and then flash a light, says Johnson, who is also a fellow in the Yang-Tan Center for Molecular Therapeutics. The most commonly used glowing protein is green fluorescent protein (GFP), which is based on a molecule originally found in a fluorescent jellyfish.

Typically a biologist can see one or two colors at the same time on a microscope, and many of the reporters out there are green, because theyre based on the green fluorescent protein, Boyden says. What has been lacking until now is the ability to see more than a couple of these signals at once.

Just like listening to the sound of a single instrument from an orchestra is far from enough to fully appreciate a symphony, Linghu says, by enabling observations of multiple cellular signals at the same time, our technology will help us understand the symphony of cellular activities.

To boost the number of signals they could see, the researchers set out to identify signals by location instead of by color. They modified existing reporters to cause them to accumulate in clusters at different locations within a cell. They did this by adding two small peptides to each reporter, which helped the reporters form distinct clusters within cells.

Its like having reporter X be tethered to a LEGO brick, and reporter Z tethered to a KNEX piece only LEGO bricks will snap to other LEGO bricks, causing only reporter X to be clustered with more of reporter X, Johnson says.

With this technique, each cell ends up with hundreds of clusters of fluorescent reporters. After measuring the activity of each cluster under a microscope, based on the changing fluorescence, the researchers can identify which molecule was being measured in each cluster by preserving the cell and staining for peptide tags that are unique to each reporter. The peptide tags are invisible in the live cell, but they can be stained and seen after the live imaging is done. This allows the researchers to distinguish signals for different molecules even though they may all be fluorescing the same color in the live cell.

Using this approach, the researchers showed that they could see five different molecular signals in a single cell. To demonstrate the potential usefulness of this strategy, they measured the activities of three molecules in parallel calcium, cyclic AMP, and protein kinase A (PKA). These molecules form a signaling network that is involved with many different cellular functions throughout the body. In neurons, it plays an important role in translating a short-term input (from upstream neurons) into long-term changes such as strengthening the connections between neurons a process that is necessary for learning and forming new memories.

Applying this imaging technique to pyramidal neurons in the hippocampus, the researchers identified two novel subpopulations with different calcium signaling dynamics. One population showed slow calcium responses. In the other population, neurons had faster calcium responses. The latter population had larger PKA responses. The researchers believe this heightened response may help sustain long-lasting changes in the neurons.

The researchers now plan to try this approach in living animals so they can study how signaling network activities relate to behavior, and also to expand it to other types of cells, such as immune cells. This technique could also be useful for comparing signaling network patterns between cells from healthy and diseased tissue.

In this paper, the researchers showed they could record five different molecular signals at once, and by modifying their existing strategy, they believe they could get up to 16. With additional work, that number could reach into the hundreds, they say.

That really might help crack open some of these tough questions about how the parts of a cell work together, Boyden says. One might imagine an era when we can watch everything going on in a living cell, or at least the part involved with learning, or with disease, or with the treatment of a disease.

Read Real Time Spying on the Symphony of Cellular Signals That Drive Biology for more on this research.

Reference: Spatial multiplexing of fluorescent reporters for dynamic imaging of signal transduction networks by Changyang Linghu, Shannon L. Johnson, Pablo A. Valdes, Or A. Shemesh, Won Min Park, Demian Park, Kiryl D. Piatkevich, Asmamaw T. Wassie, Yixi Liu, Bobae An, Stephanie A. Barnes, Orhan T. Celiker, Chun-Chen Yao, Chih-Chieh (Jay) Yu, Ru Wang, Katarzyna P. Adamala, Mark F. Bear, Amy E. Keating and Edward S. Boyden, 23 November 2020, Cell.DOI:: 10.1016/j.cell.2020.10.035

The research was funded by the Friends of the McGovern Institute Fellowship; the J. Douglas Tan Fellowship; Lisa Yang; the Yang-Tan Center for Molecular Therapeutics; John Doerr; the Open Philanthropy Project; the HHMI-Simons Faculty Scholars Program; the Human Frontier Science Program; the U.S. Army Research Laboratory; the MIT Media Lab; the Picower Institute Innovation Fund; the National Institutes of Health, including an NIH Directors Pioneer Award; and the National Science Foundation.

Read this article:
Symphony of Cellular Activities Revealed by Fluorescent Imaging Technique - SciTechDaily